First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis

Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan

(2019) Marco D DiBonaventura et al.   Therapeutics and Clinical Risk Management

Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors

(2019) Yutaka Fujiwara et al.   CANCER SCIENCE

Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-Stage Small Cell Lung Cancer (IMpower133)

(2019) Makoto Nishio et al.   Clinical Lung Cancer

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trends in Small-Cell Lung Cancer Survival in 1993–2006 Based on Population-Based Cancer Registry Data in Japan

(2018) Isao Oze et al.   JOURNAL OF EPIDEMIOLOGY

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

(2017) Toshiaki Takahashi et al.   LANCET ONCOLOGY

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

(2016) Toshio Shimizu et al.   INVESTIGATIONAL NEW DRUGS

Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors

(2016) Hidenori Mizugaki et al.   INVESTIGATIONAL NEW DRUGS

Trends in Lung Cancer Incidence Rates by Histological Type in 1975–2008: A Population-Based Study in Osaka, Japan

(2016) Fukuaki Lee Kinoshita et al.   JOURNAL OF EPIDEMIOLOGY

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody

(2015) R. Stewart et al.   Cancer Immunology Research

Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy

(2012) Ross A Soo et al.   Future Oncology

Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer1

(2010) Primo N. Lara et al.   CANCER

Japanese Lung Cancer Registry Study: First Prospective Enrollment of a Large Number of Surgical and Nonsurgical Cases in 2002

(2010) Noriyoshi Sawabata et al.   Journal of Thoracic Oncology

Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics

(2009) David R. Gandara et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER